蛋白酪氨酸激酶信号转导途径与抗肿瘤药物.docVIP

茆勇军等 : 蛋白酪氨酸激酶信号转导途径与抗肿瘤药物 ?333? 肿瘤策略也应该多途径 、 多靶点联合用药 ,可能会取 得更好的效果 ,从长期用药着眼 ,采用联合疗法也可 以降低抗药性 。 在抑制信号转导抗肿瘤成为常规治疗手段之 前 , 还 有 大 量 的 问 题 有 待 研 究 。如 im atinib、 gefitinib、erlotinib 的抗药性和副反应是亟待解决的 signaling controls tumour cell growth [ J ]. Nature, 2006, 441: 424 - 430. [ 8 ] Summy JM , Gallick GE. Treatm ent for advanced tumors: SRC reclaim s center stage [ J ]. Clin Cancer Res, 2006, 12: 1398 - 1401. [ 9 ] Schenone S, M anetti F, Botta M. 2128. [ 10 ] W eisberg E, M anley PW , Cowan 2 Jacob S W , et al . Second generation inhibitors of BCR 2 ABL for the treatm ent of im atinib 2resistant chronic myeloid leukem ia [ J ]. Nat Rev Cancer, 2007, 7: 345 - 356. [ 11 ] M urray PJ. The JAK2STAT signaling pathway: input and output integration [ J ]. J I mmunol, 2007, 178: 2623 2629. [ 12 ] Pharmap rojects V5 [ DB /OL ]. http: / /203. 156. 214. 150 / citrix / nfuse17 / frameset . asp. 2007 2 12 2 30. [ 13 ] Kamath S, Buolamwini JK . Targeting EGFR and HER 2 2 recep tor tyrosine kinases for cancer drug discovery and development [ J ]. M ed Res Rev, 2006, 26: 569 - 594. [ 14 ] Scaltriti M , Baselga J. The ep idermal grow th factor recep tor pathway: a model for targeted therapy [ J ]. Clin Cancer Res, 2006, 12: 5268 - 5272. [ 15 ] Ciardiello F, B ianco R , Caputo R , et al . Antitumor activity of ZD6474, a vascular endothelial grow th factor recep tor tyrosine kinase inhibitor, in human cancer cells w ith acquired resistance to antiep ider mal grow th factor recep tor therapy [ J ]. Clin Cancer Res, 2004, 10: 784 793. [ 16 ] W edge SR , Kendrew J, Hennequin LF, et al . AZD2171: a highly potent, orally bioavailable, vascular endothelial grow th factor recep tor2 2 2005, 65: 4389 - 4400. [ 17 ] Reid A , V idal L , Shaw H, et al . Dual inhibition of ErbB1 ( EGFR /HER1 and ErbB2 ( HER2 / neu [ J ]. Eur J Cancer, 2007, 43: 481 - 489. [ 18 ] Naumova E, Ubezio P, Garofalo A , et al . The vascular targeting p roperty of paclitaxel is enhanced by SU6668, a recep tor tyrosine kinase inhibi